Indeed, ongoing clinical trials are demonstrating promise for these immunotherapeutic agents with or without combination therapy, and the success of PD-1/PD-L1 axis therapies has invigorated the pursuit of targets exploiting other immune-tumor interactions [76]. This evidence concerns the gene CD274 and neoplasm.